Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Nguyen, Dan Vinh; Linderholm, A.; Haczku, Angela Franciska; Kenyon, Nicholas J.

doi:10.1016/j.pharmthera.2017.06.012

Cited by 43 publications

(29 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another class of insulin secretagogue, glucagon-like peptide-1 analogues, also display promising antiinflammatory effects in mouse models, 23 and have recently been proposed as potential novel treatments for obesity-associated asthma. 24 Our findings relating to insulin are consistent with those of Chen et al 7 who observed an increased risk of asthma in patients with diabetes who are regularly prescribed insulin compared with matched controls (OR 2.23, 1.52-3.58). Previous work by this group has yielded similar results.…”

Section: Univariate Hr Estimates (95% Ci)supporting

confidence: 92%

“…Our findings here may potentially demonstrate the difference between exogenous and endogenous insulin on the incidence risk of asthma, when considered alongside our results from insulin users. Another class of insulin secretagogue, glucagon‐like peptide‐1 analogues, also display promising antiinflammatory effects in mouse models, and have recently been proposed as potential novel treatments for obesity‐associated asthma …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of therapy on the risk of asthma in type 2 diabetes

Rayner

McGovern

Sherlock

et al. 2019

Clinical Respiratory J

View full text Add to dashboard Cite

Background and Objectives There are limited data about the risk of asthma in people with diabetes. We examined the incidence of asthma in subjects with type 2 diabetes (T2DM) compared to controls, and the association with metformin, sulphonylureas and insulin therapy. Materials and Methods We conducted a retrospective cohort study using a representative UK primary care database (N = 894 646 adults). We used 1:1 propensity score matching (age, gender, socio‐economic deprivation, body mass index and smoking status) to match 29 217 pairs of T2DM cases and controls. We used Cox proportional hazard regression to compare the incidence of asthma in both groups over 8 years of follow‐up. In those with T2DM, we used Cox proportional hazard regression to assess for any impact of antidiabetic medications on asthma incidence. Results Individuals with T2DM were less likely to develop asthma than matched controls (hazard ratio [HR] 0.85, 95% CI 0.77‐0.93). Insulin increased the risk of incident asthma (HR 1.25, 95% CI 1.01‐1.56), whilst metformin and sulphonylureas were associated with reduced risk (HR 0.80, 95% CI 0.69‐0.93 and HR 0.76, 95% CI 0.60‐0.97, respectively). There was no association with diabetes duration, complications or glycaemic control. Conclusions T2DM may have a protective effect against asthma development. Insulin use was associated with an increased risk of asthma, while metformin and sulphonylureas reduced the risk in those with T2DM.

show abstract

Section: Univariate Hr Estimates (95% Ci)supporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

The impact of therapy on the risk of asthma in type 2 diabetes

Rayner

McGovern

Sherlock

et al. 2019

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…[122] In addition, GLP-1 binds to RAGE and inhibits RAGE activation. [123] GLP-1 is also reported to inhibit AGEs-induced apoptosis of EC cells, increase the ratio of antiapoptosis Bcl-2/pro-apotosis Bax, downregulate cytochrome C levels, and inhibit caspase-3 and caspase-9 activities. [124] Moreover, recent studies have shown that GLP-1 can directly act on GLP-1R of ECs, which may play a role in anti-AGEs by reducing RAGE expression.…”

Section: Glp-1 Receptor Agonistmentioning

confidence: 98%

Hypoglycemic Drugs and Advanced Glycation End products

2019

ARC Journal of Diabetes and Endocrinology

View full text Add to dashboard Cite

Recent data showed that 9.1% of adults worldwide have diabetes, and 318 million adults have a high risk of developing diabetes in the future. Diabetes and its complications have serious impact on human health. In the early stages of diabetes, excessive advanced glycation endproducts (AGEs) accumulate in the body and bind to its receptor RAGE, which impairs glucose regulation. In the later stages of diabetes, increased blood glucose can accelerate the production of more AGEs. AGEs play a pivotal role in the development of diabetes and its complications. In recent years, AGEs have become one of the research hotspots. The search for potential drug targets that can block or reduce the accumulation of AGEs has attracted increasing attention. This review summarizes the role of AGEs and the effects of various hypoglycemic agents on AGEs from the perspective of mechanisms, in order to provide reference for the further search for targeted drugs against AGEs.

show abstract

“…IL-17 is able to improve the secretion of inflammatory cytokines such as IL-6, TNF- α , IL-8, CAM-1, and CM-CSF through the MAPK or NF- κ B pathway [ 56 ]. The association between obesity and neutrophil count in sputum is significant; in addition, a recent cluster analysis has shown that the presence of obesity-related asthma is characterized by increased airway neutrophils [ 57 – 59 ]. In addition to this, IL-17, IL-6, and TNF- α secreted by Th17 cells recruit and activate neutrophils in the lungs [ 60 ].…”

Section: Obesity and Asthmamentioning

confidence: 99%

Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies

Yuan

Ran

Xiong

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

Obesity, one of the most severe public health problems of the 21st century, is a common metabolic syndrome due to excess body fat. The incidence and severity of obesity-related asthma have undergone a dramatic increase. Because obesity-related asthma is poorly controlled using conventional therapies, alternative and complementary therapies are urgently needed. Lipid metabolism may be abnormal in obesity-related asthma, and immune modulation therapies need to be investigated. Herein, we describe the immune regulators of lipid metabolism in obesity as well as the interplay of obesity and asthma. These lay the foundations for targeted therapies in terms of direct and indirect immune regulators of lipid metabolism, which ultimately help provide effective control of obesity-related asthma with a feasible treatment strategy.

show abstract

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Cited by 43 publications

References 55 publications

The impact of therapy on the risk of asthma in type 2 diabetes

The impact of therapy on the risk of asthma in type 2 diabetes

Hypoglycemic Drugs and Advanced Glycation End products

Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies

Contact Info

Product

Resources

About